Little is known about the early steps of the HBV life cycle due to the lack of susceptible cells permissive for viral infection. Hence, viral entry has not been exploited for antiviral targets, but the recent seminal discovery of sodium taurocholate co-transporting polypeptide (NTCP) as the cellular receptor for HBV entry opened up many avenues of investigation, making HBV entry amenable to therapeutic intervention.
Methods
In order to exploit HBV entry, we established a HepG2-NTCP cell line that supports HBV infection. Over 70% of cells were infected at a dose of 104 genome equivalents (GEq) per cell. Several FDA-approved drugs with NTCP-inhibiting activity were tested for their ability to inhibit HBV infection of the cell line.
Results
Consistent with their NTCP inhibitory activities, our results showed that several of them inhibit HBV infection. In particular, irbesartan, a drug used for the treatment of hypertension, inhibits HBV infection at the 50% effective concentration value of 35 μM.
Conclusions
The observation that the pharmacological inhibitors of the NTCP transporter could block HBV entry suggests that NTCP represents an attractive molecular target for therapeutic intervention in HBV infection.
References
1.
El-SeragH.B.Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterol2012; 142: 1264–1273.
LamperticoP., LiawY.F.New perspectives in the therapy of chronic hepatitis B.Gut2012; 61Suppl 1: i18–i24.
6.
BlockT.M., GishR., GuoH.Chronic hepatitis B: what should be the goal for new therapies?Antiviral Res2013; 98: 27–34.
7.
UrbanS., BartenschlagerR., KubitzR., ZoulimF.Strategies to inhibit entry of HBV and HDV into hepatocytes.Gastroenterology2014; 147: 48–64.
8.
GriponP., RuminS., UrbanS.Infection of a human hepatoma cell line by hepatitis B virus.Proc Natl Acad Sci U S A2002; 99: 15655–15660.
9.
YanH., ZhongG., XuG.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.Elife2012; 1: e00049.
10.
NiY., LemppF.A., MehrleS.Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.Gastroenterology2014; 146: 1070–1083.
11.
YanH., PengB., HeW.Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.J Virol2013; 87: 7977–7991.
12.
WatashiK., SluderA., DaitoT.Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).Hepatology2014; 59: 1726–1737.
13.
NkongoloS., NiY., LemppF.A.Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.J Hepatol2014; 60: 723–731.
14.
LuciforaJ., EsserK., ProtzerU.Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.Antiviral Res2013; 97: 195–197.
15.
DongZ., EkinsS., PolliJ.E.Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).Mol Pharm2013; 10: 1008–1019.
16.
LadnerS.K., OttoM.J., BarkerC.S.Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.Antimicrob Agents Chemother1997; 41: 1715–1720.
17.
KoC., LeeS., WindischM.P., RyuW.S.DDX3 DEAD-Box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level.J Virol2014; 88: 13689–13698.
18.
IwamotoM., WatashiK., TsukudaS.Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.Biochem Biophys Res Commun2014; 443: 808–813.
19.
WatashiK., LiangG., IwamotoM.Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID).J Biol Chem2013; 288: 31715–31727.
20.
KoC., ShinY.C., ParkW.J., KimS., KimJ., RyuW.S.Residues Arg703, Asp777, and Arg781 of the RNase H domain of hepatitis B virus polymerase are critical for viral DNA synthesis.J Virol2014; 88: 154–163.
21.
KimH.Y., LiX., JonesC.T.Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals.Antiviral Res2013; 99: 6–11.
22.
PetersenJ., DandriM., MierW.Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.Nat Biotechnol2008; 26: 335–341.
23.
GriponP., DiotC., ThezeN.Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide.J Virol1988; 62: 4136–4143.
24.
DöringB., LuttekeT., GeyerJ., PetzingerE.The SLC10 carrier family: transport functions and molecular structure.Curr Top Membr2012; 70: 105–168.
25.
YanH., PengB., LiuY.Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.J Virol2014; 88: 3273–3284.
26.
KönigA., DoringB., MohrC., GeipelA., GeyerJ., GlebeD.Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.J Hepatol2014; 61: 867–875.
27.
BlanchetM., SureauC., LabonteP.Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.Antiviral Res2014; 106: 111–115.
